Effects of Ethyl Benzoate on Performance, Morphology, and Erosion of PLGA Implants Formed In Situ

被引:19
作者
Astaneh, R. [1 ]
Erfan, M. [1 ,2 ]
Barzin, J. [3 ]
Mobedi, H. [4 ]
Moghimi, Hr. [2 ]
机构
[1] Shahid Beheshti Univ Med Sci, Sch Med, Dept Biomed Engn & Med Phys, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmaceut, Tehran, Iran
[3] Iran Polymer & Petrochem Inst, Dept Biomat, Tehran, Iran
[4] Iran Polymer & Petrochem Inst, Dept Novel Drug Delivery, Tehran, Iran
关键词
Drug release; Erosion; In situ forming implant; Morphology; PLGA;
D O I
10.1002/adv.20114
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
An in Situ forming implant (ISFI) is a novel drug delivery system used for protein and peptide delivery, especially for cancer treatment. An ISFI based on 33% (w/w) poly(D,L-lactide-co-glycolide)(PLGA; 50:50)/3% (w/w) leuprolide acetate (LA)/64% (w/w) N-methyl-2-pyrrolidone (NMP) was prepared for this study. After injection of the final formulation, which is a viscous liquid to an aqueous medium, it deforms to become a semisolid or solid matrix. The performance of this matrix was investigated on the basis of peptide release from it. Erosion and morphology of ISFI were also Studied. The effects of adding 12.89% (w/w) ethyl benzoate (EB) as a rate-modifying agent on performance, erosion, and morphology of ISFI were assessed. The implant containing EB showed very low burst release (5.53% +/- 0.829%) and the morphology turns to closed pore-like structures. After adding EB, the morphology turns to closed pore-like structures. This type of morphology has very close relation to the performance of the implant as well. Finally, the effect of EB on performance, erosion, and morphology is explained by means of solvent-nonsolvent affinity, water permeation, and the rate of phase inversion. (C) 2008 Wiley Periodicals, Inc. Adv Polym Techn 27:17-26, 2008; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/adv.20114
引用
收藏
页码:17 / 26
页数:10
相关论文
共 40 条
[31]  
Perez-Marrero I, 2004, EXPERT OPIN PHARMACO, V5, P447
[32]   LEUPRORELIN - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN PROSTATIC-CANCER, ENDOMETRIOSIS AND OTHER SEX HORMONE-RELATED DISORDERS [J].
PLOSKER, GL ;
BROGDEN, RN .
DRUGS, 1994, 48 (06) :930-967
[33]   Therapeutic effects of leuprorelin microspheres in prostate cancer [J].
Sharifi, R ;
Ratanawong, C ;
Jung, A ;
Wu, Z ;
Browneller, R ;
Lee, M .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :121-138
[34]  
SOURIRAJAN S, 1989, REVERSE OSMOSIS ULTR
[35]  
Stropnik C, 1996, J APPL POLYM SCI, V61, P1821, DOI 10.1002/(SICI)1097-4628(19960906)61:10<1821::AID-APP24>3.0.CO
[36]  
2-3
[37]   MASS-TRANSFER MODELING OF ASYMMETRIC MEMBRANE FORMATION BY PHASE INVERSION [J].
TSAY, CS ;
MCHUGH, AJ .
JOURNAL OF POLYMER SCIENCE PART B-POLYMER PHYSICS, 1990, 28 (08) :1327-1365
[38]   MORE ABOUT THE DEGRADATION OF LA/GA-DERIVED MATRICES IN AQUEOUS-MEDIA [J].
VERT, M ;
LI, S ;
GARREAU, H .
JOURNAL OF CONTROLLED RELEASE, 1991, 16 (1-2) :15-26
[39]   Instability, stabilization, and formulation of liquid protein pharmaceuticals [J].
Wei, W .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 185 (02) :129-188
[40]   SELECTION CRITERIA FOR SOLVENT AND GELATION MEDIUM IN THE PHASE INVERSION PROCESS [J].
YANAGISHITA, H ;
NAKANE, T ;
YOSHITOME, H .
JOURNAL OF MEMBRANE SCIENCE, 1994, 89 (03) :215-221